Collegium Pharmaceutical, Inc. (COLL)
| Market Cap | 832.05M |
| Revenue (ttm) | 307.95M |
| Net Income (ttm) | 17.59M |
| Shares Out | 34.54M |
| EPS (ttm) | 0.51 |
| PE Ratio | 47.46 |
| Forward PE | 5.39 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $24.06 |
| Previous Close | $22.29 |
| Change ($) | 1.77 |
| Change (%) | 7.94% |
| Day's Open | 22.89 |
| Day's Range | 22.88 - 24.38 |
| Day's Volume | 582,352 |
| 52-Week Range | 13.89 - 25.45 |
– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million –
Collegium Pharmaceutical recently reported their Q3 earnings with a beat on EPS and revenue. Despite some serious COVID-19 headwinds, Collegium was able to record another quarter of growth and...
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead f...
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.
STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursda...
These three health-related businesses are well positioned to provide market-beating gains.
STOUGHTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain managem...
STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain manag...
STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain man...
STOUGHTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain manag...
Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -4.17% and 4.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for th...
– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 –
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wedne...
Collegium Pharmaceuticals - Whether It's Too Cheap
These are the two healthcare stocks that possess the best value for the greatest reward in May.
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2020 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Collegium (COLL).
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2019 Results - Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2019 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2....
Investors aren't happy about the drugmaker's proposed senior convertible note offering.
Collegium Pharmaceutical: 2020 Could Be A Great Year
STOUGHTON, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000...
The speciality pharmaceutical company purchased the full rights to an important drug product.
Collegium Pharmaceutical Inc. (NASDAQ: COLL) shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics.
Prospects Appear Bright for Small Drug Industry in 2020
Collegium Pharmaceutical Is A Relatively Safe Opioid Pick For 2020
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to th...
This biotech stock is promising strong revenue figures and a net profit for 2020.
– Xtampza® ER Revenues Expected in the Range of $150.0 Million to $160.0 Million for 2020 –
Market Is Turning A Blind Eye To Collegium's Lack Of Debt And Opioid Lawsuits
STOUGHTON, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain manage...
Buying proven businesses is better than scouring the pink sheets looking for a viable investment.
STOUGHTON, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain manage...
Investors are excited about the drugmaker's big formulary wins for its abuse-deterrent opioid drug.
Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q3 2019 Results - Earnings Call Transcript
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -12.50% and -1.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead...
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About COLL
Collegium Pharmaceutical, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date May 7, 2015 |
| CEO Joseph Ciaffoni | Employees 255 |
| Stock Exchange NASDAQ | Ticker Symbol COLL |
Financial Performance
In 2019, COLL's revenue was $296.70 million, an increase of 5.81% compared to the previous year's $280.41 million. Losses were -$22.72 million, -41.93% less than in 2018.
Analyst Forecasts
According to 10 analysts, the average rating for COLL stock is "Buy." The 12-month stock price forecast is 28.43, which is an increase of 18.16% from the latest price.